{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:38:22Z","timestamp":1777934302673,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T00:00:00Z","timestamp":1519344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>Mitomycin C as a treatment for superficial bladder carcinomas and upper urinary tract tumours has been linked to local adverse events. Systemic toxicity has been documented for just a very few cases. This report presents a case of interstitial pneumonitis accompanied by myelosuppression in a 74-year-old patient after receiving the fifth administration of mitomycin C through a ureteral catheter as a treatment for left kidney pyelocaliceal urothelial carcinoma. Therefore, suspecting mitomycin C toxicity, urinary tract instillations were discontinued, and intravenous filgrastim and methylprednisolone were initiated. Currently, after five months since the last mitomycin C urinary tract instillation, the patient is still receiving filgrastim and corticosteroids. A moderate effort dyspnoea persists despite interstitial pulmonary infiltrates have presented a very important reduction. Pancytopenia has also persisted. Blood count and lung function monitoring would be appropriate in patients undergoing mitomycin C instillations, especially in those with established prior lung disease.<\/jats:p>","DOI":"10.1177\/1078155218760160","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T23:50:51Z","timestamp":1519429851000},"page":"739-742","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Interstitial pneumonitis and myelosuppression associated to mitomycin C urinary tract instillations: A case report"],"prefix":"10.1177","volume":"25","author":[{"given":"Montserrat","family":"Rodriguez-Reyes","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hospital Clinic of Barcelona, Catalonia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Marco-Hernandez","sequence":"additional","affiliation":[{"name":"Department of ICU, Hospital Clinic of Barcelona, Catalonia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Castro-Rebollo","sequence":"additional","affiliation":[{"name":"Department of ICU, Hospital Clinic of Barcelona, Catalonia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Soy-Muner","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital Clinic of Barcelona, Catalonia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,2,23]]},"reference":[{"key":"bibr1-1078155218760160","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.6.8.1273"},{"key":"bibr2-1078155218760160","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7796.115746"},{"key":"bibr3-1078155218760160","unstructured":"British Columbia Cancer Agency. Mitomycin health professional monograph: cancer drug manual [online manual]. Vancouver, BC. Revised 1 April 2016, www.bccancer.bc.ca\/drug-database-site\/Drug%20Index\/Mitomycin_monograph_1Apr2016.pdf (accessed 10 February 2018)."},{"key":"bibr4-1078155218760160","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr5-1078155218760160","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(92)90241-S"},{"key":"bibr6-1078155218760160","unstructured":"Product Information. Mitomycin C Kyowa\u00ae. Bristol-Myers Squibb, Australia Pty Ltd, 2010."},{"key":"bibr7-1078155218760160","doi-asserted-by":"publisher","DOI":"10.1016\/S0210-4806(09)74237-8"},{"key":"bibr8-1078155218760160","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937010-00004"},{"key":"bibr9-1078155218760160","first-page":"5144","volume":"51","author":"Dalton JT","year":"1991","journal-title":"Cancer Res"},{"key":"bibr10-1078155218760160","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900101)65:1<23::AID-CNCR2820650107>3.0.CO;2-Q"},{"key":"bibr11-1078155218760160","volume-title":"Cancer chemotherapy handbook","author":"Dorr RT","year":"1980"},{"key":"bibr12-1078155218760160","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0523-4"},{"key":"bibr13-1078155218760160","first-page":"41","volume":"26","author":"Neubauer H","year":"1987","journal-title":"Urologe A"},{"key":"bibr14-1078155218760160","first-page":"641","volume":"18","author":"Cuervo Pinna MA","year":"2001","journal-title":"An Med Interna"},{"key":"bibr15-1078155218760160","doi-asserted-by":"publisher","DOI":"10.1159\/000280383"},{"key":"bibr16-1078155218760160","doi-asserted-by":"crossref","unstructured":"Yao H, Cabalag M, DeSousa A, et\u00a0al. Myelosuppression following adjuvant mitomycin C for upper tract urothelial carcinoma. BJUI, www.bjuinternational.com\/case-studies\/myelosuppression-following-adjuvant-mitomycin-c-for-upper-tract-urothelial-carcinoma\/ (2012, accessed 12 March 2017).","DOI":"10.1002\/BJUIw-2011-149-web"},{"key":"bibr17-1078155218760160","doi-asserted-by":"publisher","DOI":"10.1016\/S0094-0143(21)00419-5"},{"key":"bibr18-1078155218760160","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65854-3"},{"key":"bibr19-1078155218760160","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)44908-1"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155218760160","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155218760160","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155218760160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:18:07Z","timestamp":1777688287000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155218760160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,23]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1177\/1078155218760160"],"URL":"https:\/\/doi.org\/10.1177\/1078155218760160","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,23]]}}}